As filed with Securities and Exchange Commission on July 15, 2019
Registration
No. 333-231143
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Post-Effective
Amendment No. 1
to
FORM
S-1
on FORM S-3
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
AILERON THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
13-4196017
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
490 Arsenal Way, Suite 210
Watertown, Massachusetts 02472
(617)
995-0900
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Manuel C. Alves Aivado, M.D., Ph.D.
President and Chief Executive Officer
Aileron Therapeutics, Inc.
490 Arsenal Way, Suite 210
Watertown, Massachusetts 02472
(617)
995-0900
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Stuart M. Falber
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000
Approximate date of commencement of proposed sale to public:
From time to time after this Registration Statement is declared effective.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box. ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that
shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the
following box. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and
emerging growth company in
Rule 12b-2
of the Exchange Act.
|
|
|
|
|
Large accelerated filer ☐
|
|
|
|
Accelerated filer ☐
|
|
|
|
Non-accelerated filer ☒
|
|
|
|
Smaller reporting company ☒
|
|
|
|
|
|
|
|
Emerging growth company ☒
|
If an emerging growth company, indicate by check mark if the registrant has not elected to use the extended
transition period for complying with any new or revised financial accounting standards provided in Section 7(a)(2)(B) of the Securities Act. ☒
This filing
constitutes a Post-Effective Amendment to the Registration Statement on Form S-1 (File No. 333-231143), which was initially declared effective on May 14, 2019. This Post-Effective Amendment shall hereafter become effective in accordance with Section
8(c) of the Securities Act of 1933, as amended (the Securities Act), on such date as the Securities and Exchange Commission, acting pursuant to Section 8(c) of the Securities Act, may determine.